Biogen Inc. $BIIB Shares Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 67.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,350 shares of the biotechnology company’s stock after purchasing an additional 37,350 shares during the quarter. Biogen accounts for approximately 1.5% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 26th largest holding. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $16,253,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BIIB. WPG Advisers LLC grew its stake in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC grew its stake in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares during the period. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC grew its stake in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Up 0.0%

Shares of BIIB stock opened at $200.05 on Friday. The stock’s fifty day moving average is $188.73 and its two-hundred day moving average is $184.31. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The firm has a market capitalization of $29.54 billion, a P/E ratio of 21.46 and a beta of 0.20. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts expect that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Oppenheimer lifted their price target on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Barclays assumed coverage on shares of Biogen in a research note on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target on the stock. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price target for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Finally, Royal Bank Of Canada lifted their price target on shares of Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and an average price target of $217.26.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.